FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2901390919> ?p ?o ?g. }

• W2901390919 endingPage "349" @default.
• W2901390919 startingPage "337" @default.
• W2901390919 abstract "Summary Glecaprevir coformulated with pibrentasvir (G/P) is approved to treat hepatitis C virus ( HCV ) infection and was highly efficacious in phase 2 and 3 studies. Treating HCV genotype ( GT ) 3 infection remains a priority, as these patients are harder to cure and at a greater risk for liver steatosis, fibrosis progression and hepatocellular carcinoma. Data were pooled from five phase 2 or 3 trials that evaluated 8‐, 12‐ and 16‐week G/P in patients with chronic HCV GT 3 infection. Patients without cirrhosis or with compensated cirrhosis were either treatment‐naïve or experienced with interferon‐ or sofosbuvir‐based regimens. Safety and sustained virologic response 12 weeks post‐treatment ( SVR 12) were assessed. The analysis included 693 patients with GT 3 infection. SVR 12 was achieved by 95% of treatment‐naïve patients without cirrhosis receiving 8‐week (198/208) and 12‐week (280/294) G/P. Treatment‐naïve patients with cirrhosis had a 97% (67/69) SVR 12 rate with 12‐week G/P. Treatment‐experienced, noncirrhotic patients had SVR 12 rates of 90% (44/49) and 95% (21/22) with 12‐ and 16‐week G/P, respectively; 94% (48/51) of treatment‐experienced patients with cirrhosis treated for 16 weeks achieved SVR 12. No serious adverse events ( AE s) were attributed to G/P; AE s leading to study drug discontinuation were rare (<1%). G/P was well‐tolerated and efficacious for patients with chronic HCV GT 3 infection, regardless of cirrhosis status or prior treatment experience. Eight‐ and 12‐week durations were efficacious for treatment‐naïve patients without cirrhosis and with compensated cirrhosis, respectively; 16‐week G/P was efficacious in patients with prior treatment experience irrespective of cirrhosis status." @default.
• W2901390919 created "2018-11-29" @default.
• W2901390919 creator A5002183213 @default.
• W2901390919 creator A5005658827 @default.
• W2901390919 creator A5008225974 @default.
• W2901390919 creator A5010240694 @default.
• W2901390919 creator A5019176590 @default.
• W2901390919 creator A5026654277 @default.
• W2901390919 creator A5027413766 @default.
• W2901390919 creator A5028367378 @default.
• W2901390919 creator A5029165106 @default.
• W2901390919 creator A5035416018 @default.
• W2901390919 creator A5052859844 @default.
• W2901390919 creator A5054617732 @default.
• W2901390919 creator A5058318375 @default.
• W2901390919 creator A5064442417 @default.
• W2901390919 creator A5064535615 @default.
• W2901390919 creator A5066214063 @default.
• W2901390919 creator A5073412832 @default.
• W2901390919 creator A5076572995 @default.
• W2901390919 creator A5078808298 @default.
• W2901390919 creator A5081795781 @default.
• W2901390919 creator A5085966620 @default.
• W2901390919 creator A5088842832 @default.
• W2901390919 creator A5089993955 @default.
• W2901390919 date "2018-12-11" @default.
• W2901390919 modified "2023-10-01" @default.
• W2901390919 title "Glecaprevir/Pibrentasvir in patients with chronic <scp>HCV</scp> genotype 3 infection: An integrated phase 2/3 analysis" @default.
• W2901390919 cites W1759807482 @default.
• W2901390919 cites W1858796636 @default.
• W2901390919 cites W1868139921 @default.
• W2901390919 cites W1941992522 @default.
• W2901390919 cites W1966188054 @default.
• W2901390919 cites W2003780225 @default.
• W2901390919 cites W2035804055 @default.
• W2901390919 cites W2037251110 @default.
• W2901390919 cites W2039857559 @default.
• W2901390919 cites W2042063943 @default.
• W2901390919 cites W2044203022 @default.
• W2901390919 cites W2049370512 @default.
• W2901390919 cites W2078251659 @default.
• W2901390919 cites W2080468761 @default.
• W2901390919 cites W2117027295 @default.
• W2901390919 cites W2119168386 @default.
• W2901390919 cites W2120733999 @default.
• W2901390919 cites W2121209352 @default.
• W2901390919 cites W2150652264 @default.
• W2901390919 cites W2163028749 @default.
• W2901390919 cites W2185218296 @default.
• W2901390919 cites W2282504480 @default.
• W2901390919 cites W2289667014 @default.
• W2901390919 cites W2309068205 @default.
• W2901390919 cites W2522557924 @default.
• W2901390919 cites W2578013986 @default.
• W2901390919 cites W2588942442 @default.
• W2901390919 cites W2601629064 @default.
• W2901390919 cites W2605116305 @default.
• W2901390919 cites W2617500612 @default.
• W2901390919 cites W2697901486 @default.
• W2901390919 cites W2744191372 @default.
• W2901390919 cites W2765116944 @default.
• W2901390919 cites W2784719900 @default.
• W2901390919 cites W2788216918 @default.
• W2901390919 doi "https://doi.org/10.1111/jvh.13038" @default.
• W2901390919 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7379735" @default.
• W2901390919 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30421537" @default.
• W2901390919 hasPublicationYear "2018" @default.
• W2901390919 type Work @default.
• W2901390919 sameAs 2901390919 @default.
• W2901390919 citedByCount "27" @default.
• W2901390919 countsByYear W29013909192019 @default.
• W2901390919 countsByYear W29013909192020 @default.
• W2901390919 countsByYear W29013909192021 @default.
• W2901390919 countsByYear W29013909192023 @default.
• W2901390919 crossrefType "journal-article" @default.
• W2901390919 hasAuthorship W2901390919A5002183213 @default.
• W2901390919 hasAuthorship W2901390919A5005658827 @default.
• W2901390919 hasAuthorship W2901390919A5008225974 @default.
• W2901390919 hasAuthorship W2901390919A5010240694 @default.
• W2901390919 hasAuthorship W2901390919A5019176590 @default.
• W2901390919 hasAuthorship W2901390919A5026654277 @default.
• W2901390919 hasAuthorship W2901390919A5027413766 @default.
• W2901390919 hasAuthorship W2901390919A5028367378 @default.
• W2901390919 hasAuthorship W2901390919A5029165106 @default.
• W2901390919 hasAuthorship W2901390919A5035416018 @default.
• W2901390919 hasAuthorship W2901390919A5052859844 @default.
• W2901390919 hasAuthorship W2901390919A5054617732 @default.
• W2901390919 hasAuthorship W2901390919A5058318375 @default.
• W2901390919 hasAuthorship W2901390919A5064442417 @default.
• W2901390919 hasAuthorship W2901390919A5064535615 @default.
• W2901390919 hasAuthorship W2901390919A5066214063 @default.
• W2901390919 hasAuthorship W2901390919A5073412832 @default.
• W2901390919 hasAuthorship W2901390919A5076572995 @default.
• W2901390919 hasAuthorship W2901390919A5078808298 @default.
• W2901390919 hasAuthorship W2901390919A5081795781 @default.
• W2901390919 hasAuthorship W2901390919A5085966620 @default.
• W2901390919 hasAuthorship W2901390919A5088842832 @default.
• W2901390919 hasAuthorship W2901390919A5089993955 @default.

• next